DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Neutropenia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Neutropenia (184)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include neutropenia. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 184   Next >>

Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin Hydrochloride
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in male

Reported by a physician from Germany on 2012-08-24

Patient: male

Reactions: Febrile Neutropenia, Skin Infection, Neutropenia, Pneumonitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Doxorubicin Hydrochloride
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-06
    End date: 2012-04-20

Prednisolone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-21

Rituximab
    Dosage: 750 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-01
    End date: 2012-04-16

Vincristine
    Dosage: 2 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Other drugs received by patient: MST / 00036302 /; Novalgin / 00169801 /; Rulid; Pantoprazole; Paspertin / 00041902 /; Acyclovir; Electrolytes NOS W / Macrogol 3350; Dipyrone INJ; Metoclopramide; Acyclovir



Possible Vincristine side effects in female

Reported by a physician from Thailand on 2012-08-24

Patient: female, weighing 57.4 kg (126.3 pounds)

Reactions: Neutropenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl



Possible Vincristine side effects in 52 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24

Patient: 52 year old female

Reactions: Tumour Lysis Syndrome, Posterior Reversible Encephalopathy Syndrome, Insomnia, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Daunorubicin HCL
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Daunorubicin HCL
    Dosage: at 50% dosage

Dexamethasone
    Indication: Premedication

Methylprednisolone Sodium Succinate
    Indication: B Precursor Type Acute Leukaemia

Prednisone TAB
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Vincristine
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Other drugs received by patient: Ondansetron; Voriconazole; Morphine Sulfate; Morphine



Possible Vincristine side effects in 17 year old male

Reported by a physician from Poland on 2012-08-23

Patient: 17 year old male

Reactions: Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Pyrexia, Renal Failure, Neutropenia, Clostridial Infection, Septic Shock

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cefepime

Doxorubicin Hydrochloride
    Indication: Ewing's Sarcoma

Etoposide
    Indication: Ewing's Sarcoma Metastatic

Ifosfamide
    Indication: Ewing's Sarcoma Metastatic

Meropenem

Metronidazole

Netromycin

Vancocin Hydrochloride

Vincristine
    Indication: Ewing's Sarcoma Metastatic

Other drugs received by patient: Fluconazole; Caspofungin Acetate



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male, weighing 55.2 kg (121.4 pounds)

Reactions: Unresponsive To Stimuli, Moaning, Neutropenia, Septic Shock, Cardiac Arrest

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Mercaptopurine
    Start date: 2009-08-21

Methotrexate Sodium

Prednisone

Vincristine
    End date: 2012-08-10



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in female

Reported by a physician from United States on 2012-08-20

Patient: female, weighing 70.8 kg (155.8 pounds)

Reactions: Abdominal Pain, Hyperpyrexia, Anaphylactic Reaction, Chills, Pain, Hepatic Failure, Transaminases Increased, Splenic Infarction, Loss of Consciousness, Aortic Thrombosis, Off Label Use, Malaise, C-Reactive Protein Increased, Myositis, Dyspnoea, Hypotension, Arrhythmia, Lung Consolidation, Hypophosphataemia, Zygomycosis, Bacteraemia, Ventricular Tachycardia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Shock, Infusion Related Reaction

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Cytarabine
    Dosage: day 1,8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23

Decadron Phosphate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23

Doxil
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Methotrexate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2005-01-01
    End date: 2007-01-01

PEG-Asparaginase
    Dosage: day 2, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-25
    End date: 2007-10-25

Velcade
    Dosage: day 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Vincristine
    Dosage: day 1,8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Vincristine side effects in female

Reported by a physician from United States on 2012-08-14

Patient: female, weighing 70.8 kg (155.8 pounds)

Reactions: Abdominal Pain, Rhabdomyolysis, Hyperpyrexia, Chills, Anaphylactic Reaction, Bone Pain, Hepatic Failure, Transaminases Increased, Loss of Consciousness, Aortic Thrombosis, Splenic Infarction, Hypokalaemia, Malaise, C-Reactive Protein Increased, Dyspnoea, Hypotension, Hypophosphataemia, Zygomycosis, Bacteraemia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Lung Infiltration, Shock, Infusion Related Reaction

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 70 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2005-01-01
    End date: 2007-10-23

Decadron Phosphate
    Dosage: 9 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Doxorubicin HCL
    Dosage: 107 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Methotrexate Sodium
    Dosage: unk, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2005-01-01
    End date: 2007-01-01

Pegaspargase
    Dosage: unk, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-25

Velcade
    Dosage: 1.3 mg/m2, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Vincristine
    Dosage: 2 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-07

Patient:

Reactions: Hospitalisation, Neuropathy Peripheral, Vomiting, Febrile Neutropenia, Neutropenia, Neutrophil Count Decreased, Lymphoma

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: for 5 days
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: for 5 days
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: B-Cell Lymphoma

Rituximab
    Indication: B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in 76 year old

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02

Patient: 76 year old

Reactions: Lung Disorder, Neutropenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: daily for 5 days
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in 58 year old male

Reported by a health professional (non-physician/pharmacist) on 2012-08-02

Patient: 58 year old male, weighing 77.0 kg (169.4 pounds)

Reactions: Haemoglobin Decreased, White Blood Cell Count Decreased, Platelet Count Decreased, Neutropenia

Drug(s) suspected as cause:
Asparaginase (Unspecified) (Asparginase) (Unknown)
    Indication: Chemotherapy
    Start date: 2012-03-12

Cyclophosphamide
    Indication: Chemotherapy
    Start date: 2012-03-12

Dexamethasone
    Indication: Chemotherapy
    Start date: 2012-03-12

Doxorubicin HCL
    Indication: Chemotherapy
    Start date: 2012-03-12

Isavuconazole (Isavuconazole)
    Dosage: three times daily, intravenous (not otherwise specified)
    Indication: Fungal Infection
    Start date: 2012-02-07
    End date: 2012-02-09

Vincristine
    Indication: Chemotherapy
    Start date: 2012-03-12

Other drugs received by patient: Metronidazole; Ciprofloxacin



Possible Vincristine side effects in 17 year old male

Reported by a physician from Poland on 2012-08-01

Patient: 17 year old male

Reactions: Renal Failure, Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Neutropenia, Clostridial Infection, Septic Shock

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Indication: Ewing's Sarcoma

Etoposide
    Indication: Ewing's Sarcoma Metastatic

Ifosfamide
    Indication: Ewing's Sarcoma Metastatic

Vincristine
    Indication: Ewing's Sarcoma Metastatic



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-01

Patient: male

Reactions: Neutropenia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Mabthera
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-08-01

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-31

Patient:

Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Chemoradiation
    Indication: Hodgkin's Disease

Cyclophosphamide
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Prednisone
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 17 year old male

Reported by a physician from Poland on 2012-07-27

Patient: 17 year old male

Reactions: Renal Failure, Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Neutropenia, Septic Shock, Clostridial Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Indication: Ewing's Sarcoma

Etoposide
    Indication: Ewing's Sarcoma Metastatic

Ifosfamide
    Indication: Ewing's Sarcoma Metastatic

Vincristine
    Indication: Ewing's Sarcoma Metastatic



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-27

Patient:

Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Epirubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone and Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female, weighing 53.0 kg (116.6 pounds)

Reactions: Anaemia, Neutropenia, Hypokalaemia

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-12-23

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-12-23

Furosemide

Prednisone
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-12-23

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-12-23



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-26

Patient:

Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Chemoradiation
    Indication: Hodgkin's Disease

Cyclophosphamide
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Prednisone
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-07-25

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: 100 mg on days 1-5 for chop and r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 375 mg/m2 on day 1 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-07-19

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-18

Patient: male

Reactions: Neutropenia

Drug(s) suspected as cause:
Cyclophosphamide

Doxorubicin HCL

Mabthera
    Indication: B-Cell Lymphoma

Prednisone

Vincristine



Possible Vincristine side effects in

Reported by a physician from Japan on 2012-07-17

Patient:

Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Neupogen
    Indication: B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Rituxan
    Dosage: 6 doses-2 days prior to each cycle of chop
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in 18 year old male

Reported by a physician from Canada on 2012-07-17

Patient: 18 year old male

Reactions: Bronchopulmonary Aspergillosis, Aspergillosis, Arthritis Bacterial, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in male

Reported by a physician from Germany on 2012-07-16

Patient: male

Reactions: Neutropenia, Lymphocytic Infiltration

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17
    End date: 2012-04-17

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17
    End date: 2012-04-17

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-16
    End date: 2012-04-16

Neulasta
    Indication: B-Cell Lymphoma
    Start date: 2012-04-20
    End date: 2012-04-20

Prednisolone
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2012-04-16
    End date: 2012-04-21

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17
    End date: 2012-04-17

Other drugs received by patient: Metoclopramide; Morphine Sulphate Drip; Acyclovir; Dipyrone TAB; Pantoprazole



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-13

Patient:

Reactions: Neuropathy Peripheral, Neutropenia, Infection, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-821 day cycles; n=28
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-821 day cycles; n=28

Obinutuzumab
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012